Piper Sandler analyst Matt O’Brien last night upgraded Zimmer Biomet to Overweight from Neutral with a price target of $145, up from $135. The analyst cites favorable commentary on the "large" joint market at the American Academy of Orthopaedic Surgeons conference and the company’s "conservative" guidance for the upgrade. Feedback from numerous sources were that surgical orthopedic volumes through the first two months of the year are very strong, the analyst tells investors in a research note. The firm now believes there may be upside to Zimmer’s 3%-5% revenue guidance range for 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet upgraded to Overweight from Neutral at Piper Sandler
- Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2023
- Zimmer Biomet price target raised to $140 from $125 at Loop Capital
- Zimmer Biomet price target raised to $130 from $120 at Canaccord
- Zimmer Biomet price target raised to $137 from $135 at Truist